CREATE Medicines
Private · United States
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
4
in active trials · 5 in all
Trials
4 active
5 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
In vivo CD19 CAR-T, mRNA in lipid nanoparticles |
Phase 1/2 | 1 Dec 2028Phase 1/2 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 1 Dec 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Autoimmune Diseases, Systemic Lupus Erythematosus and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Jan 2027Phase 1 trial completes | |||
| Next date | 31 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | HER2-Expressing Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Aug 2027Phase 1 trial completes | |||
| Next date | 31 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Epithelial Tumors, Malignant | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2027Phase 1 trial completes | |||
| Next date | 31 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma | ||||
| Open drug page | |||||
About
- No active trial
- MT-101
- SEC filings
- None: CREATE Medicines is private
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev